Orlistat
Brand names: Xenical, Alli
Orlistat is an oral lipase inhibitor used as an adjunct to a reduced-calorie, lower-fat diet for the management of obesity and overweight with associated risk factors.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits gastric and pancreatic lipases within the gastrointestinal tract, reducing the breakdown and absorption of dietary fat, which is then excreted.
Prescribing in practice
- Gastrointestinal effects such as oily stools, faecal urgency and flatulence are common and are worsened by a high-fat diet, so a lower-fat diet is essential.
- It can reduce absorption of fat-soluble vitamins, so a multivitamin taken at bedtime is often recommended.
- It may reduce absorption of some medicines, including ciclosporin, levothyroxine and certain antiepileptics, and may affect oral contraception if severe diarrhoea occurs.
Monitoring
Monitor weight response and review at intervals, continuing only if a meaningful weight loss is achieved within the recommended period.
Counselling the patient
- Follow a reduced-fat diet to gain benefit and minimise the unpleasant gastrointestinal effects.
- Take a multivitamin at bedtime to maintain fat-soluble vitamin intake.
- Use additional contraceptive precautions if severe diarrhoea occurs, and separate from levothyroxine dosing.
Evidence & guidelines
Orlistat is recommended by NICE as a pharmacological adjunct to lifestyle measures in obesity when defined weight-loss targets are met.
Reference: NICE CG189; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Ranson Criteria (Pancreatitis) · Pancreatitis
- Pancreatic Fistula Risk Score (FRS) after Pancreatoduodenectomy · Pancreatic Surgery
- CT Severity Index (CTSI/Balthazar) for Acute Pancreatitis · Acute Pancreatitis
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016